Want to see LIVN full AI Analyst Report?
Top Page
LivaNova
(NASDAQ:LIVN)
Select Model
Select Model
Rating:69Neutral
Price Target:
$93.00
▲(16.29% Upside)
Action:Downgraded
Date:08/05/26
The score is driven primarily by improving financial performance (profitability rebound and better leverage) and strong technical momentum with the stock above key moving averages. These positives are tempered by a premium valuation (high P/E with no dividend) and near-term cash flow pressure from higher CapEx and reduced free cash flow guidance, despite raised revenue and EPS outlook.
Positive Factors
Raised revenue and EPS outlook
Higher full-year revenue and EPS guidance indicates sustained demand, effective execution and improving operating leverage. The upgrades across both core segments support a stronger earnings base over the next several quarters.
Negative Factors
Lower free cash flow outlook
The reduced cash flow outlook shows that earnings growth is currently requiring substantial investment and may convert less efficiently into cash. Persistent pressure on free cash flow could constrain deleveraging, acquisitions or shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Raised revenue and EPS outlook
Higher full-year revenue and EPS guidance indicates sustained demand, effective execution and improving operating leverage. The upgrades across both core segments support a stronger earnings base over the next several quarters.
Read all positive factors
LivaNova (LIVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.51B
Dividend YieldN/A
Average Volume (3M)670.92K
Price to Earnings (P/E)23.4
Beta (1Y)0.92
Revenue Growth12.39%
EPS GrowthN/A
CountryUS
Employees3,300
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)3.45
Shares Outstanding55,093,506
10 Day Avg. Volume617,382
30 Day Avg. Volume670,917
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.79
Price to Sales (P/S)2.42
P/FCF Ratio19.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$88.20Price Target Upside10.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)4.34
Revenue Forecast (FY)$1.52B
LivaNova Business Overview & Revenue Model
Company Description
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products...
How the Company Makes Money
LivaNova makes money primarily by selling medical devices and the recurring consumables and services associated with their use, with revenue generally recognized at the time products are delivered (subject to customer terms) and over time for cert...
LivaNova Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call presented a predominantly positive operational and financial story: record revenue and EPS, raised top-line and EPS guidance, strong growth and market-share gains in Cardiopulmonary and Epilepsy, strategic supply and manufacturing actions (Thermo Fisher agreement, new production line), and compelling clinical data supporting future adoption. Offsetting items are largely strategic investments (higher CapEx, R&D, IT), a one-time tariff refund that boosted margins and EPS in the quarter but will not recur, modest delays in OSA regulatory timing, and a lowered near-term free cash flow outlook. On balance the positive execution, guidance increases and durable innovation pipeline outweigh the near-term cash and one-time headwind items.Positive Updates
Record Quarterly Revenue and EPS
Revenue of $391 million in Q2 2026, up 9.8% on a constant currency basis vs. prior year. Adjusted diluted EPS of $1.26 vs. $1.05 in Q2 2025 (approximately +20%).
Negative Updates
One-Time Tariff Refund Benefit
A $6 million net IEEPA tariff refund in the quarter provided approximately +150 basis points to gross margin and contributed $0.08 to adjusted diluted EPS; management said this benefit is one-time and not expected in future periods.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue and EPS
Revenue of $391 million in Q2 2026, up 9.8% on a constant currency basis vs. prior year. Adjusted diluted EPS of $1.26 vs. $1.05 in Q2 2025 (approximately +20%).
Read all positive updates
Company Guidance
LivaNova raised its full‑year 2026 guidance, now forecasting revenue growth of 8%–9% on a constant‑currency basis (up from 7%–8%) with foreign‑exchange tailwind of roughly 1%; adjusted diluted EPS is now expected to be $4.30–$4.40 (≈11.5% growth at midpoint) with adjusted operating income margin of 20%–21% and an adjusted effective tax rate of ~23%, and adjusted diluted weighted average shares of ~56 million. Segment guidance was also raised: Cardiopulmonary revenue is now expected to grow 9.5%–10.5% (vs. prior 8.5%–9.5%) with Essenz ~80% of HLM placements in 2026 (up from 55% in 2025), and Epilepsy revenue is guided to 7%–8% (vs. prior 6%–7%). The company increased full‑year CapEx to $135 million (from $120 million) and reduced adjusted free cash flow guidance to $140M–$160M (from $160M–$180M), noting an estimated tariff net impact on full‑year adjusted operating income of less than $5 million (ex‑IEEPA).LivaNova Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
70
Positive
Cash Flow
64
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.47B | 1.39B | 1.25B | 1.15B | 1.02B | 1.04B |
| Gross Profit | 1.00B | 939.90M | 870.87M | 771.25M | 707.23M | 705.99M |
| EBITDA | 180.71M | -129.50M | 202.52M | 38.48M | 30.90M | -6.33M |
| Net Income | 188.58M | -242.50M | 63.23M | 17.55M | -86.25M | -135.82M |
Balance Sheet | ||||||
| Total Assets | 2.64B | 2.61B | 2.51B | 2.43B | 2.29B | 2.20B |
| Cash, Cash Equivalents and Short-Term Investments | 516.62M | 635.60M | 428.86M | 266.50M | 214.17M | 207.99M |
| Total Debt | 351.95M | 473.30M | 676.77M | 640.40M | 580.43M | 286.70M |
| Total Liabilities | 1.32B | 1.41B | 1.19B | 1.15B | 1.09B | 906.31M |
| Stockholders Equity | 1.33B | 1.20B | 1.32B | 1.28B | 1.21B | 1.29B |
Cash Flow | ||||||
| Free Cash Flow | 148.34M | 173.20M | 135.93M | 39.93M | 43.40M | 77.07M |
| Operating Cash Flow | 249.26M | 254.30M | 183.04M | 74.91M | 69.90M | 102.54M |
| Investing Cash Flow | -99.81M | -72.90M | -48.16M | -40.33M | -38.40M | 36.90M |
| Financing Cash Flow | -222.95M | -285.70M | 18.55M | 21.48M | 280.10M | -181.48M |
LivaNova Technical Analysis
Positive
79.97
Price Trends
80.63
Positive
76.10
Positive
69.92
Positive
Market Momentum
0.35
Negative
51.50
Neutral
64.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIVN, the sentiment is Positive. The current price of 79.97 is below the 20-day moving average (MA) of 80.35, below the 50-day MA of 80.63, and above the 200-day MA of 69.92, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 51.50 is Neutral, neither overbought nor oversold. The STOCH value of 64.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LIVN.
LivaNova Risk Analysis
LivaNova disclosed 34 risk factors in its most recent earnings report. LivaNova reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LivaNova Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $3.12B | 19.97 | 32.97% | ― | 25.82% | 108.84% | |
71 Outperform | $2.24B | 30.04 | 16.72% | ― | 7.32% | 7.24% | |
71 Outperform | $1.82B | 13.33 | 17.62% | ― | 4.35% | 161.83% | |
69 Neutral | $4.51B | 23.39 | 15.41% | ― | 12.39% | ― | |
68 Neutral | $4.30B | 34.20 | 7.43% | ― | 2.62% | 53.15% | |
56 Neutral | $1.25B | -421.64 | -0.71% | 1.15% | 16.40% | 85.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
LIVN
LivaNova
78.93
22.41
39.65%
AORT
Artivion
25.22
-15.82
-38.55%
ITGR
Integer Holdings
125.86
23.39
22.83%
UFPT
Ufp Technologies
278.59
77.38
38.46%
INSP
Inspire Medical Systems
66.48
-12.29
-15.60%
TMDX
TransMedics Group
86.40
-21.39
-19.84%
LivaNova Corporate Events
Business Operations and StrategyExecutive/Board ChangesStock BuybackFinancial DisclosuresShareholder Meetings
LivaNova Shareholders Back 2026 AGM Proposals and Governance
Positive
Jun 11, 2026
LivaNova PLC held its 2026 Annual General Meeting of Shareholders on June 10, 2026, where investors approved the election of eleven directors for terms expiring at the 2027 AGM and endorsed the company’s U.S. and UK executive compensation re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.